11b-Hydroxysteroid Dehydrogenase Type 1 (11b-HSD1) Inhibition: tissue-specific control of cortisol action (360G-Wellcome-086058_Z_08_A)
Professor Brian Walker, Professor Jonathan Seckl and Dr Scott Webster, University of Edinburgh have identified 11b-HSD1 as a crucial amplifier of glucocorticoid action in liver, adipose tissue and CNS, have shown its pathophysiological significance in obesity, and have provided preclinical and clinical 'proof of concept' that 11b-HSD1 inhibition improves both Metabolic Syndrome and cognitive function in ageing. Although their work has fuelled intense commercial interest in developing 11b-HSD1 inhibitors for metabolic indications, including type 2 diabetes, the opportunity to improve cognitive function has not yet attracted pharmaceutical companies. Under the latest round of funding, they will select the optimal clinical candidate and aim to progress these to Phase I clinical trials aiming at a memory improvement.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 195834 |
| Applicant Surname | Walker |
| Approval Committee | Seeding Drug Discovery Committee |
| Award Date | 2010-05-19T00:00:00+00:00 |
| Financial Year | 2009/10 |
| Grant Programme: Title | Seeding Drug Discovery Award |
| Internal ID | 086058/Z/08/A |
| Lead Applicant | Prof Brian Walker |
| Partnership Value | 195834 |
| Planned Dates: End Date | 2012-03-31T00:00:00+00:00 |
| Planned Dates: Start Date | 2008-07-01T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | Scotland |